📰 Springwork Annual Report News
Springwork Annual Report News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Springwork Annual Report. Real-time updates on events, politics, business and more.
April 24, 2024
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
February 29, 2024
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in...
February 27, 2024
– Reported OGSIVEO™ net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to...
April 18, 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of B...
April 18, 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifiraf...
April 17, 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 -- MapKure, LLC, SpringWorks Therapeutics, Inc. , and BeiGene, Ltd. , today... | April 17, 2023
April 17, 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 -- SpringWorks Therapeutics, Inc. , and BeiGene, Ltd. , today announced that they will present updated... | April 17, 2023
September 7, 2022
STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. SWTX, a clinical-stage biopharmaceutical company focused on develop
September 7, 2022
Strengthens Financial Position to Over $600 Million in Cash, Cash Equivalents and Marketable Securities, Upon Closing of the Financing ...